Adjuvant and neoadjuvant approaches in early-stage HCC

Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, gives an overview of emerging immunotherapy approaches in earlier stages of hepatocellular carcinoma (HCC). Neoadjuvant therapy has resulted in enhanced response rates, even in resectable cases, and post-resection pathologic complete response may be a predictor of overall survival. The Phase III IMbrave150 trial (NCT03434379) has additionally demonstrated the efficacy of atezolizumab with bevacizumab in the adjuvant setting. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.